RIVM launches study on long-term effectiveness of COVID-19 vaccines RIVM is launching an extensive study today to research the long-term effectiveness of the various COVID-19 vaccines in the Netherlands.
Situation in the Netherlands remains concerning In the week from 10 to 16 March, 39,527 people received a positive test result for COVID-19, nearly 25% more than in the week before that. The reproduction number completely above 1 this week. Sander Koning
Prospects not looking good yet The number of people who were tested for SARS-CoV-2 increased by 20% last week. The number of people who tested positive rose by 7%. The reproduction number also rose above 1.
Care workers in nursing homes and small-scale residential facilities invited for COVID-19 vaccination starting today As of today, the ca. 269,000 care workers of nursing homes and small-scale residential facilities in the Netherlands are invited to make an appointment for a COVID-19 vaccination.
Spread of tick-borne encephalitis virus in the Netherlands Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.
Environmental radioactivity in the Netherlands : Results in 2017 RIVM reports annually on the level of radioactivity that occurs under normal circumstances in the environment and food.
iGEM meetup for teams and supervisors The best synbio projects, including iGEM teams, have one thing in common: cutting edge science in the light of carefully considered societal needs.
Rubber granulate on synthetic turf fields causes environmental impact Use of rubber granulate sourced from car tyres, on synthetic turf fields can be harmful to the environment in the close vicinity of these fields.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.